These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 27161546)

  • 1. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
    Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
    Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
    Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension.
    Lee HY; Kim KI; Ihm SH; Rhee MY; Sohn IS; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
    Clin Ther; 2021 Oct; 43(10):1746-1756. PubMed ID: 34503866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
    Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
    Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
    Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
    Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
    Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
    Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of treating prehypertension with an angiotensin-receptor blocker.
    Julius S; Nesbitt SD; Egan BM; Weber MA; Michelson EL; Kaciroti N; Black HR; Grimm RH; Messerli FH; Oparil S; Schork MA;
    N Engl J Med; 2006 Apr; 354(16):1685-97. PubMed ID: 16537662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
    Edes I;
    Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
    Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
    Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
    Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
    Oparil S; Levine JH; Zuschke CA; Gradman AH; Ripley E; Jones DW; Hardison JD; Cushing DJ; Prasad R; Michelson EL
    Am J Cardiol; 1999 Aug; 84(3):289-93. PubMed ID: 10496437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.